The level of minimal residual disease (MRD) early in treatment of acute lymphoblastic leukemia (ALL) strongly predicts the risk of marrow relapse. As a variety of methods of varying complexity have been separately used for detecting and quantifying MRD, we compared the prognostic utility of three methodsmeasurement of blast percentage on day 14 of treatment, detection of monoclonality on day 14 or day 35, and measurement of MRD by PCR-based limiting dilution analysis on day 14 or day 35. The study group comprised 38 children aged 1-15 with Philadelphia-negative B-lineage ALL who were uniformly treated and followed until relapse or for a minimum of 5 years. We also studied some of the technical factors which influence the ability to detect MRD. Measurement of blast percentage on day 14 by an expert morphologist, detection of monoclonality on day 35, and PCR-based measurement of MRD levels on days 14 and 35 all showed significant ability to divide patients into prognostic groups. Measurement of blast percentage on day 14 by routine morphology or detection of monoclonality on day 14 were not useful. The quality of DNA samples varied greatly, as determined by amplifiability in the PCR. However, virtually all amplifiable leukemic targets in a sample were detectable which suggests that the level of detection achieved by limiting dilution analysis is essentially determined by the amount of DNA which it is practicable to study. We conclude that quantification of MRD at the end of induction provides the full range of prognostic information for marrow relapse but is complex; detection of monoclonality on day 35 is simple and has good positive predictive value; and quantification of MRD on day 14 merits further study. PCR-based methods for measurement of MRD levels should incorporate a correction for variation in DNA amplifiability. Leukemia (2001) 15, 385-390. 
Introduction
A number of studies in childhood acute lymphoblastic leukemia (ALL) have now shown that detection and/or quantification of minimal residual disease (MRD) in bone marrow during or at the end of induction, or during the first few months of treatment, provides information of strong prognostic value. [1] [2] [3] [4] [5] [6] [7] [8] [9] The hope for the future is that this information may be used to guide and improve treatment. A variety of techniques have been used for studying MRD. The majority of groups have used techniques based upon the PCR and these have varied greatly in complexity and in the amount of quantitative information they provide. At the one extreme, there are simple techniques, such as detection of a monoclonal gene rearrangement using consensus primers, which is non-quantitative and is capable of detecting leukemia down to a level of approximately 10 −3 . 10, 11 At the other extreme, there is detection of a monoclonal gene rearrangement using two clone-specific primers which, together with a sensitive quantitation method such as limiting dilution analysis, 12 is capable of accurate quantitation probably down to 10 −5 to 10 −6 . In between there are several methods of intermediate complexity, in which some specificity for the leukemic clone is obtained by specific probing or use of a single specific primer, and which are more quantitative or less quantitative, depending on the exact detection technique used. There is also the simple approach using morphology wherein the percentage of leukemic blasts is measured by microscopy after 7 or 14 days of treatment. This technique is not particularly sensitive but thus far it is the only technique which has been shown to improve outcome when used to alter treatment. 13 In 1994 we reported a study of a group of children with standard risk acute lymphoblastic leukemia (ALL) in whom long-term outcome could be very precisely predicted by sensitive quantification of MRD at the end of induction. 1 In the same group of patients, detection at that time of a monoclonal gene rearrangement using consensus primers showed good positive predictive value but poor negative predictive value. 14 Although the results for this group of patients were quite clear, the DNA had been obtained by scraping cells off stored marrow slides. The small amount of DNA obtained may have limited the amount of information that was derived from these patients.
We have now re-examined and compared the two endpoints, quantification and detection of monoclonality, in a new series of patients using DNA obtained from frozen marrow samples. In addition, we have studied morphological and molecular quantification of leukemia on day 14 of treatment and have compared findings and conclusions across the two studies.
Patients and methods

Patients
Between December 1991 and October 1995, 52 children were diagnosed with acute lymphoblastic leukemia and treated at the Women's and Children's Hospital, Adelaide, the South Australian State Referral Centre. Four who were less than 1 year old received an infant treatment regimen; six who had T-lineage ALL received an intensive Australian and New Zealand Children's Cancer Study Group (ANZCCSG) Study VI treatment protocol, as did two who had the t(9;22) at diagnosis. The remaining 40 received standard ANZCCSG Study VI treatment. One patient died 3 days after the start of induction treatment and provided no marrow samples. A second patient died shortly after completing induction treatment. This left a cohort of 38 B-lineage ALL patients who attained clinical remission after a single round of induction treatment, and for whom reasonable follow-up was available. These 38 form the basis of this study.
The median age at diagnosis was 3.4 years (range 1.3-15.9), the median white cell count was 11.0 × 10 9 /l (range 0.5-305.2), and there were 14 males and 24 females. Cytogenetic information was obtainable for 31 patients; two had t(1;19), one had t(1;3;12), one had trisomy 5, one was hypodiploid, nine were hyperdiploid, and the remainder were pseudodiploid or diploid.
Marrow aspirates:
All 38 patients had marrow aspirated at diagnosis, on day 14, and on day 35 for routine morphology studies. However, the amount of marrow collected varied, and insufficient was left over for molecular studies from six patients on day 14 and from two patients on day 35.
Treatment:
The 5 2 ) thrice weekly for 3 weeks. The final doses of vincristine, daunorubicin and asparaginase were given on day 21. Intrathecal methotrexate was given on days 1 and 22. Subsequent therapy involved consolidation, CNS prophylaxis, and maintenance treatment. After 1 year patients were randomized to receive either maintenance treatment alone or maintenance plus a course of reinduction/ reconsolidation. The overall 5-year event-free survival for all patients in ANZCCSG Study VI is 59%.
Methods
Blast count on day 14:
An experienced senior hematologist measured the number of blasts in 500 cells on a fixed stained smear from a day 14 bone marrow aspirate, without knowing the patient's identity. Blast counts were also done on 200 cells by a hospital registrar as part of the routine reporting system.
Detection of monoclonality:
The CDR3 regions of the rearranged immunoglobulin heavy chain (IgH) gene and the T cell receptor ␥ chain (TCR␥) gene were amplified in duplicate as previously described. 10, 15, 16 PCR products were separated by polyacrylamide gel electrophoresis and examined visually under UV light after staining with ethidium bromide. Monoclonality (or oligoclonality) was defined by the presence on electrophoresis of one (or several) homogeneous PCR products which were identical in both duplicates.
Sensitive quantification of MRD:
MRD was quantified on days 14 and 35 by using the CDR3 region of the rearranged IgH gene as a molecular marker for cells of the leukemic clone and the N-ras gene as a molecular marker for all cells. 17 For each patient the rearranged IgH gene was sequenced and a pair of 'leukemia-specific' primers was synthesized. The numbers of amplifiable leukemic targets and amplifiable N-ras targets were quantified by PCR using limiting dilution analysis, which involved multiple replicates and Poisson statistics, 12 and the proportion of nucleated marrow cells which belong to the leukemic clone was calculated assuming each leukemic cell contains one rearranged IgH gene and all cells contain two N-ras genes. For samples in which leukemia could not be detected, an upper limit value for the level of MRD could be calculated from the number of amplifiable genomes studied.
Outcomes:
Two patients withdrew early due to adverse side-effects, at 0.4 and 2.1 years, and were censored at the time of withdrawal. Other patients were followed until first relapse or until June 2000.
Statistics:
Data were analyzed by Kaplan-Meier analysis with a one-tailed log rank test and by Cox proportional hazard modelling. When analyzing the relationship between MRD level and relapse in marrow, patients with isolated extramedullary relapse were censored at the time of relapse.
Ethics:
This study was approved by the Committee on Clinical Investigation, Flinders Medical Centre.
Results
Of the 38 patients, 16 relapsed; 11 of these relapses involved marrow, three involved testis alone, and two involved the CNS alone. Apart from the two patients who were withdrawn early, the follow-up in patients who did not relapse ranged from 5.2 to 8.4 years.
A monoclonal IgH and/or TCR gene rearrangement was detected at diagnosis in 34 of the 38 patients (89%). Molecular quantification was established for 27 of these 34 patients, ie in 71% of the total number. Of the other seven patients, two produced amplified IgH PCR products that were similar in size and difficult to separate for direct sequencing, three gave sequence which was difficult to read, probably due to poor amplification of the IgH rearrangement found in the leukemic clone, and in the remaining two the clone-specific primers were not sensitive enough for limiting dilution quantification.
DNA quality
The proportion of N-ras targets that were amplifiable from fresh or frozen marrow was measured in 94 samples. The results are shown in the upper panel of Figure 1 and are compared with the results of the earlier Study V, in which DNA was recovered from cells on slides. The median fraction of amplifiable ras genomes for Study VI was 0.20 compared with 0.34 for Study V (P = 0.06, two-tailed). In 20% of samples, fewer than 15% of N-ras genomes were amplifiable and in 5% of samples, fewer than 1% were amplifiable. The proportion of leukemic IgH targets that were amplifiable was taken to be the same as the proportion of N-ras targets that were amplifiable. The DNA from diagnostic samples was diluted in 1 g of DNA from normal peripheral blood lymphocytes and the proportions of amplifiable leukemic targets which could be detected were determined. The results of Studies V and VI are shown in the lower panel of Figure 1 . The median proportion of amplifiable leukemic genomes The proportions of N-ras gene targets which were amplifiable in each patient sample (upper panel) and the proportion of amplifiable leukemic gene targets which were detectable in the patient samples obtained at diagnosis (lower panel). The proportions are ranked by magnitude. which could be detected was 0.70 in Study V and 0.59 in Study VI. This finding indicated that nearly every leukemic target could be detected even in the presence of a large excess of heterogeneous IgH targets derived from normal cells.
Day 14
Morphology:
Routine morphology was performed on all 38 patients. No patients were identified with blast counts Ͼ25%. Two patients had a blast count Ͼ5% and both ultimately relapsed in the marrow. The senior hematologist studied material from 33 of the 38 patients and identified five with a blast count of at least 5%. They were different patients from the two identified through routine morphology. Four of the five patients with blasts у5% subsequently relapsed in marrow whereas only five of 28 patients with a blast count Ͻ5% did so (P = 0.0028, Figure 2a) .
Detection of monoclonality:
Twenty-six patients were studied. The group of nine in whom no monoclonal population was detected did better but the difference between the two groups was not statistically significant (P = 0.18).
Molecular quantification:
This was performed in 20 patients and the results are shown in Figure 2b . Five patients had MRD Ͼ10 −2 and all subsequently relapsed in marrow. Monoclonality had been detected in all of these five patients Leukemia but an elevated blast count was observed in only two. The level of MRD was Ͻ10 −2 in 15 patients and five relapsed, two in the marrow, two in the testis only, and one in CNS only. There was a highly significant difference (P = 0.0002) in the incidence of marrow relapse between patients with MRD у10 −2 and patients with MRD Ͻ10 −2 .
Day 35
Morphology: All patients were in morphological remission with blast counts Ͻ5%.
Detection of monoclonality (Figure 2c):
Thirty-one patients were studied. Six had the monoclonal leukemic population detected and four subsequently relapsed in the marrow (P = 0.013) and one in the CNS.
Molecular quantification (Figure 2d):
Five of the 27 patients studied had MRD Ͼ10 −3 and four (80%) subsequently relapsed, all in the marrow. The other 22 had MRD Ͻ10 and eight (36%) relapsed, four in the marrow, two in the CNS only, and two in the testis only). For marrow relapses, the difference between MRD у10 −3 and Ͻ10 −3 was significant (P = 0.010). Patients were also classified as having high (Ͼ10 −3 ), intermediate (10 −3 to 2 × 10 −5 ) or low (Ͻ2 × 10 −5 ) MRD. One patient who provided only a small marrow sample with no detectable leukemia could not be included as she might have belonged to either the intermediate or low MRD group. There was a significant difference between survival curves and patients with low MRD did best (P = 0.010, logrank). Cox proportional hazard modelling suggested that the trend towards better outcomes with lower MRD was significant (P = 0.03). Compared to low MRD patients, the risk of relapse was 2.5 times (95% confidence limits, 1.1-5.6) higher in the group with intermediate MRD and 6.1 (2.7-13.9) times higher in the group with high MRD.
Extramedullary relapse
Four quantified patients had isolated extramedullary relapse, two in the testis and two in the CNS. There was no clear relationship between the level of marrow MRD on day 35 and isolated extramedullary relapse (Figure 3 ).
Discussion
The level of MRD early during drug treatment of ALL strongly predicts long-term outcome, particularly in children. At the present time, measurement of the level of MRD can be used to define prognosis but, in the future, it may also be useful in making decisions on treatment.
A number of methods for detecting and quantifying MRD have been used and they vary greatly in their complexity and in the amount of information they provide. At one extreme, the most complex methods are able to quantify MRD down to a level of 10 −5 to 10 −6 and define, with a high degree of certainty, patients with a high, intermediate or low probability of relapse. While these methods are suitable for research studies, they are too complex for routine use. The question arises whether simpler methods might provide an acceptable ). Patients with isolated extramedullary relapse were censored at the time of relapse. The figure also shows the number of patients in each subgroup.
Figure 3
Sites of relapse in relation to level of MRD in marrow on day 35 (᭹ MRD detected, ᭺ MRD was not detected but was less than value shown, as determined from the number of amplifiable genomes studied). Only patients followed until relapse or for at least 5 years after diagnosis are shown.
compromise between the degree of complexity and the amount of useful information. To some extent, the answer depends on the purpose for which the method is being used: whether to identify patients with a high level of MRD and a high probability of relapse, who might benefit if treatment were to be increased or altered; whether to identify patients with a low level of MRD and a high probability of cure, who might be able to safely receive treatment of lesser intensity; or whether to study the biology of the disease during treatment and the effects of new therapies. Simple methods, with a low sensitivity of detection, are likely to be of most use for identifying high risk patients, whereas highly sensitive but quantitative methods, which are likely to be complex, will be necessary for identifying low risk patients and for research.
Measurement of blast number by microscopy on day 7 or day 14 of induction is simple, and has been correlated with outcome in a number of studies. A review of the results of 15 trials in which early response was measured by morphology of marrow or blood showed that overall a 'slower' early response 18 was associated with a two-to a seven-fold increase in the risk of relapse, compared to a more rapid response. Importantly, the Children's Cancer Group reported that intensification of therapy improved outcome in children who had poor prognosis ALL and who had a blast percentage of Ͼ25% in the day 7 marrow. 13 In the present study, examination of the marrow on day 14 by an experienced hematologist and using a cut-off of 5% blasts had a positive predictive value of 75% and a sensitivity of 30% for the identification of marrow relapse. However, routine morphology, as carried out by a variety of observers, performed poorly -although the two patients having blasts Ͼ5% both relapsed, the other nine patients who ultimately relapsed in marrow were not identified. Quantification of blasts by morphology is simple but it is quite observer-dependent and, when the number of leukemic blasts is low, their identification becomes difficult and the statistical uncertainty of counting becomes high.
Detection of monoclonality by PCR is also relatively simple and has a level of detection of approximately 10 −3 , a level which virtually all groups agree will identify high-risk patients. [1] [2] [3] [4] [5] [6] [7] [8] In early studies of ANZCCSG Study V patients (treated 1985-1989), using material scraped from fixed stained bone marrow smears we reported that detection of monoclonality on day 35, by electrophoresis on standard polyacrylamide gels and subsequent staining, had a positive predictive value for relapse of 37.5%. Using fluorescent consensus primers and Genescan, detection of monoclonality after 20 weeks of treatment was reported to have a positive predictive value of 89% and a sensitivity of 57%. 19 In the present study, detection of monoclonality at day 35 using visual inspection of standard polyacrylamide gels and marrow relapse as the end-point had a positive predictive value of 67% and a sensitivity of 40%. The improved positive predictive value of monoclonality detection in the present study over the previous study is probably due to the technical improvement resulting from the greater amount of DNA which was recovered from the samples in Study VI. Until simpler quantitative techniques become available, detection of monoclonality will probably be a good compromise for clinical use in detection of patients with high levels of MRD who are likely to relapse. A positive result with this test at the end of induction or shortly thereafter is highly predictive of relapse, although a negative result provides little information. Immunological detection of leukemic cells may be an alternative test of clinical value. 4 It provides quantitative information down to MRD levels of approximately 10 −4 but it is more complex and applicable to a lower proportion of patients.
In this study sensitive MRD quantification using patient-specific primers and quantification by limiting dilution analysis with multiple replicates and Poisson statistics provided the most information. For identification of marrow relapse, a day 14 cut off of 10 −2 provided a positive predictive value of 100% and a sensitivity of 71%; Panzer-Grumayer et al 20 and, in preliminary form, de Haas et al 21 have also reported that day 14 estimation of MRD is prognostically useful. If the prognostic value of day 14 measurement of MRD were to be generally confirmed, then MRD at this time could become very useful as a guide to treatment, as it would enable treatment decisions to be made in a more timely manner. The level of leukemia on day 14 is often interpreted as being a function of the rate of response to treatment. However, recent evidence suggests that the leukemic population at diagnosis may consist of two subpopulations, a major subpopulation which is relatively sensitive to chemotherapy and decreases rapidly, and a minor one which is relatively resistant. 22 If so, the level of leukaemia on day 14 may be determined more by the size of the relatively resistant subpopulation than by the rate of response.
Quantification of MRD on day 35 also provided information which was highly prognostic. In agreement with our previous results individuals with MRD Ͼ10 −3 had a high probability of relapse, those with MRD from 10 −3 to 2 × 10 −5 had an intermediate probability and those with MRD Ͻ2 × 10 −5 had a low probability. Many groups have likewise found that relapse is extremely likely if the MRD level is Ͼ10 −3 at the end of induction or shortly thereafter. [1] [2] [3] [4] [5] [6] [7] [8] Importantly, several groups have now confirmed the low likelihood of relapse if the MRD level is very low. Thus Gruhn et al, 7 also using quantification by limiting dilution analysis, observed no relapses in patients with undetectable MRD or a level Ͻ2 × 10 −5 at the end of induction. Cave et al 5 using competitive PCR quantification, which would have had a level of detection of 10
, found a relapse rate of 9-10% in patients with undetectable MRD at the end of induction or in the few months thereafter; and van Dongen et al, 6 using a probing technique with a sensitivity of at least 10 −4 , found a relapse rate of 2% in patients with undetectable MRD. The minor differences in results are probably attributable to differences in treatment protocols or measurement techniques. We conclude that all studies of MRD at the end of induction or shortly thereafter essentially agree that measurement of MRD will provide excellent prognostic information over the whole range of prognosis in childhood ALL, provided only that the technique used is quantitative and is able to detect low levels of disease.
In our previous analyses of MRD and outcomes, in Study IV (patients diagnosed [1980] [1981] [1982] [1983] [1984] and in Study V (1985-1990), we found that MRD level in marrow did not obviously predict relapse outside the marrow. The same observation was Leukemia made in the present study. Thus, either there is no true relationship between the level of MRD in marrow at the end of induction and the risk of relapse in extramedullary sites, or the relationship is too weak to be detectable, given the small proportion of patients who relapse outside the marrow. Different methods for detection or quantification of MRD differ in the level of MRD that they are able to detect. In this study, the technique of limiting dilution analysis showed that a signal could be obtained from virtually every rearranged IgH gene, even against a background of 1 g of normal DNA. The normal DNA was derived from separated peripheral blood mononuclear cells and would have contained at least 10 times the number of rearranged IgH genes as would the same mass of DNA derived from marrow cells. The efficiency of detection of the leukemic IgH rearrangement against this background of non-leukemic rearrangements indicates that the level of detection of limiting dilution analysis is essentially determined by the amount of DNA that can be studied. Thus by use of multiple replicates, a level of detection of 10 −5 or even 10 −6 can be readily achieved for marrow cells.
The use of quantification of MRD has several limitations which are not always appreciated and which may affect interpretation of the result. The level of MRD will obviously depend on the intensity of treatment and the time of sampling. The ability to measure low levels of MRD depends on both the quantity and quality of the DNA obtained. The quantity of DNA is an important determinant of both the proportion of patients in whom MRD can be detected and the level of quantification that can be achieved. In our analysis of Study V, in which DNA was extracted from material on microscope slides, MRD could be detected and quantified in only 18 of 44 patients (41%), whereas in the present analysis, in which DNA was extracted from frozen cells, MRD could be detected and quantified in 20 of 27 patients (74%). The quality of DNA recovered from the microscope slides in Study V was slightly better than that of DNA recovered from stored cells in Study VI, although the difference did not reach statistical significance. However, the overall quality of DNA in both studies was surprisingly low with fewer than 15% of N-ras targets being amplifiable in 20% of samples and fewer than 1% in 5% of samples. The ability to detect low levels of disease is severely compromised by such samples and erroneous quantification of MRD will result unless correction is made for impaired amplifiability.
